中科微点-全球专利检索

  1. Login
  2. Sign Up

Search Results

96 records (took 0.031 seconds)

    Malaria antigens and methods of use
    21.
    发明授权
    Malaria antigens and methods of use 有权

    公开(公告)号：US10022432B2

    公开(公告)日：2018-07-17

    申请号：US15800975

    申请日：2017-11-01

    Applicant: GenVec, Inc.

    Inventor： Ping Chen ,  Duncan McVey ,  Douglas E. Brough ,  Joseph Bruder

    IPC: A61K39/015 ,  A61K39/00

    Abstract: The invention is directed to a composition comprising one or more polypeptides or one or more nucleic acid sequences that can induce a protective immune response against Plasmodium species that infect humans. The invention also is directed to a method of using such compositions to induce a protective immune response against a Plasmodium parasite in a mammal.

    METHOD FOR PROPAGATING ADENOVIRAL VECTORS ENCODING INHIBITORY GENE PRODUCTS
    25.
    发明申请
    METHOD FOR PROPAGATING ADENOVIRAL VECTORS ENCODING INHIBITORY GENE PRODUCTS 审中-公开
    用于传播编码基因产物的腺病毒载体的方法

    公开(公告)号：US20140273228A1

    公开(公告)日：2014-09-18

    申请号：US14288493

    申请日：2014-05-28

    Applicant: GenVec, Inc.

    Inventor： Jason G.D. Gall ,  Douglas E. Brough ,  C. Richter King

    IPC: C12N15/86

    CPC classification number: C12N15/635 ,  C12N7/00 ,  C12N15/86 ,  C12N2710/10343 ,  C12N2710/10352 ,  C12N2830/006

    Abstract: The invention provides a method of propagating an adenoviral vector. The method comprises (a) providing a cell comprising a cellular genome comprising a nucleic acid sequence encoding a tetracycline operon repressor protein (tetR), and (b) contacting the cell with an adenoviral vector comprising a heterologous nucleic acid sequence encoding a toxic protein. The heterologous nucleic acid sequence is operably linked to a promoter and one or more tetracycline operon operator sequences (tetO), and expression of the heterologous nucleic acid sequence is inhibited in the presence of tetR, such that the adenoviral vector is propagated. The invention also provides a system comprising the aforementioned cell and adenoviral vector.

    Abstract translation: 本发明提供了一种繁殖腺病毒载体的方法。 该方法包括（a）提供包含细胞基因组的细胞，所述细胞基因组包含编码四环素操纵子阻遏蛋白（tetR）的核酸序列，和（b）使细胞与包含编码毒性蛋白质的异源核酸序列的腺病毒载体接触。 异源核酸序列可操作地连接到启动子和一个或多个四环素操纵子操纵子序列（tetO），并且异源核酸序列的表达在tetR存在下被抑制，使得腺病毒载体被繁殖。 本发明还提供了包含上述细胞和腺病毒载体的系统。

    METHODS OF GENE THERAPY FOR TREATING DISORDERS OF THE EAR BY ADMINISTERING A VECTOR ENCODING AN ATONAL-ASSOCIATED FACTOR
    26.
    发明申请
    METHODS OF GENE THERAPY FOR TREATING DISORDERS OF THE EAR BY ADMINISTERING A VECTOR ENCODING AN ATONAL-ASSOCIATED FACTOR 审中-公开
    通过管理编码相关因子的矢量来治疗耳朵疾病的基因治疗方法

    公开(公告)号：US20140005257A1

    公开(公告)日：2014-01-02

    申请号：US14024749

    申请日：2013-09-12

    Applicant: GENVEC, INC.

    Inventor： Douglas E. Brough

    IPC: A61K38/17

    CPC classification number: A61K38/17 ,  A61K38/00 ,  A61K48/005 ,  A61P27/00 ,  C07K14/4702 ,  C12N7/00 ,  C12N15/86 ,  C12N2501/60 ,  C12N2710/10343

    Abstract: The invention is directed to a method of changing the sensory perception of an animal. The method comprises administering an expression vector comprising a nucleic acid sequence encoding an atonal-associated factor, which is expressed to produce the atonal-associated factor resulting in generation of hair cells that allow perception of stimuli in the inner ear. Also provided is a method of generating a hair cell in differentiated sensory epithelia in vivo. The method comprises contacting differentiated sensory epithelial cells with an adenoviral vector (a) deficient in one or more replication-essential gene functions of the E1 region and E4 region, (b) comprising a spacer in the E4 region, and (c) comprising a nucleic acid sequence encoding an atonal-associated factor. The nucleic acid sequence is expressed to produce the atonal-associated factor such that a hair cell is generated. An adenoviral vector encoding an atonal-associated factor also is provided.

    Abstract translation: 本发明涉及一种改变动物的感觉知觉的方法。 所述方法包括施用包含编码无关联因子的核酸序列的表达载体，所述核酸序列被表达以产生导致产生能够感知内耳中的刺激的毛细胞的无关性因子。 还提供了一种在体内在分化感觉上皮细胞中产生毛细胞的方法。 该方法包括使分化的感觉上皮细胞与E1区和E4区的一个或多个复制必需基因功能缺陷的腺病毒载体（a）接触，（b）在E4区中包含间隔基，和（c）包含 编码无关联因子的核酸序列。 表达核酸序列以产生无创因子，从而产生毛细胞。 还提供了编码无关联因子的腺病毒载体。

    Method for enhancing bone density or formation
    28.
    发明申请
    Method for enhancing bone density or formation 审中-公开
    增强骨密度或形成的方法

    公开(公告)号：US20030158132A1

    公开(公告)日：2003-08-21

    申请号：US10053637

    申请日：2002-01-22

    Applicant: GenVec, Inc.

    Inventor： Imre Kovesdi

    IPC: A61K048/00 ,  C12N005/08

    CPC classification number: C07K14/52 ,  A61K48/00 ,  C07K14/47 ,  C07K14/475 ,  C07K2319/00 ,  C07K2319/02 ,  C12N9/16 ,  C12N2799/022

    Abstract: The invention pertains to a method for enhancing bone density or formation. In accordance with the method, a nucleic acid encoding a secreted alkaline phosphatase (SEAP) is administered to a cell in a region of a bone such that the nucleic acid is expressed to produce the SEAP, whereby bone density or formation is enhanced within the region. The method can be employed to produce a bone graft having a cell harboring an exogenous nucleic acid encoding a SEAP. To facilitate the inventive method, the invention provides a recombinant viral vector having a nucleic acid encoding a SEAP. Optionally, a nucleic acid encoding an angiogenic protein and/or a nucleic acid encoding an osteogenic protein is employed in conjunction with the nucleic acid encoding a SEAP.

    Abstract translation: 本发明涉及一种增强骨密度或形成的方法。 根据该方法，将编码分泌的碱性磷酸酶（SEAP）的核酸施用于骨的区域中的细胞，使得所述核酸被表达以产生SEAP，从而在该区域内增强骨密度或形成 。 该方法可用于产生具有含有编码SEAP的外源核酸的细胞的骨移植物。 为了促进本发明的方法，本发明提供了具有编码SEAP的核酸的重组病毒载体。 任选地，编码血管生成蛋白和/或编码成骨蛋白的核酸的核酸与编码SEAP的核酸结合使用。

    Therapeutic regimen for treating cancer
    29.
    发明申请
    Therapeutic regimen for treating cancer 审中-公开
    治疗癌症的治疗方案

    公开(公告)号：US20030086903A1

    公开(公告)日：2003-05-08

    申请号：US10001017

    申请日：2001-11-02

    Applicant: GenVec, Inc.

    Inventor： Henrik S. Rasmussen ,  Karen W. Chu

    IPC: A01N063/00

    CPC classification number: A61K35/761 ,  A61K38/191 ,  C12N2710/10332 ,  C12N2710/10341 ,  A61K2300/00

    Abstract: The present invention provides a method for reducing the size of a tumor in a human comprising (a) directly injecting into the tumor, via multiple injections to different points of the tumor, a dose of a pharmaceutical composition comprising (i) a pharmaceutically acceptable carrier and (ii) a replication-deficient adenoviral vector comprising a nucleic acid sequence encoding TNF-null operably linked to a promoter, wherein the dose comprises about 1null107 to about 4null1012 3 particle units (pu) of replication-deficient adenoviral vector, two or more times over a therapeutic period comprising up to 10 weeks, and (b) administering a dose of ionizing radiation over the duration of the therapeutic period, whereby the size of the tumor is reduced.

    Abstract translation: 本发明提供了一种减少人体肿瘤大小的方法，包括（a）通过多次注射直接注射到肿瘤中，药物组合物的剂量包含（i）药学上可接受的载体 其包含可操作地连接到启动子的编码TNF-α的核酸序列的复制缺陷型腺病毒载体，其中所述剂量包含约1×10 7至约4×10 12 3个复制缺陷型腺病毒载体的颗粒单位（pu），两个或更多个 包括长达10周的治疗期，以及（b）在治疗期间内施用一定剂量的电离辐射，从而降低肿瘤的大小。

Patent Agency Ranking